Karyopharm Therapeutics (KPTI) EBT Margin (2016 - 2025)
Historic EBT Margin for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to 300.08%.
- Karyopharm Therapeutics' EBT Margin fell 1986800.0% to 300.08% in Q4 2025 from the same period last year, while for Dec 2025 it was 134.18%, marking a year-over-year decrease of 815500.0%. This contributed to the annual value of 134.18% for FY2025, which is 815500.0% down from last year.
- As of Q4 2025, Karyopharm Therapeutics' EBT Margin stood at 300.08%, which was down 1986800.0% from 75.14% recorded in Q3 2025.
- Karyopharm Therapeutics' EBT Margin's 5-year high stood at 55.76% during Q2 2024, with a 5-year trough of 300.08% in Q4 2025.
- In the last 5 years, Karyopharm Therapeutics' EBT Margin had a median value of 99.24% in 2025 and averaged 110.18%.
- Its EBT Margin has fluctuated over the past 5 years, first surged by 1596200bps in 2022, then plummeted by -1986800bps in 2025.
- Over the past 5 years, Karyopharm Therapeutics' EBT Margin (Quarter) stood at 30.57% in 2021, then tumbled by -483bps to 117.11% in 2022, then fell by -6bps to 124.32% in 2023, then rose by 18bps to 101.4% in 2024, then plummeted by -196bps to 300.08% in 2025.
- Its last three reported values are 300.08% in Q4 2025, 75.14% for Q3 2025, and 98.11% during Q2 2025.